Biotechnology & Life Sciences

Stock Code

LCT

Stock Exchange

ax

Living Cell Technologies (LCT) injects healthy cells to replace or repair damaged organs without the use of toxic drugs. The company targets Huntington's disease, stroke, type 1 diabetes and haemophilia. LCT's product portfolio consists of NeurotrophinCell (potential treatment of diseases of nervous system such as Huntington's disease and stroke), Fac8Cell (producing factor 8, blood clotting agent absent or defective in people suffering haemophilia) and DiabeCell (treatment of insulin-dependent diabetes).

Stock Code

ICV

Stock Exchange

ax

Incitive (ICV) is a pharmaceuticals & biotechnology company. Its aim is to become a sustainable Life Science company by in-licensing leads at the discovery stage, taking them through preclinical studies which will create significant value-add, and partner with large pharmaceutical or biotechnology companies for the clinical phase. ICV was listed on the ASX on 5 May 2006.

Stock Code

IMU

Stock Exchange

ax

Imugene (IMU) is an animal health biopharmaceutical company developing and commercialising biological products for the intensively farmed pig and poultry industries. Imugene's products have advantages over existing 'health improving' products, including (1) substantially improving the health of animals;(2) improving productivity and profitability for poultry and pig producers; and (3) reducing consumer exposure to antibiotic, hormone and chemical residues by using safe biodegradable, biological treatments, thereby reducing development of antibiotic resistant ‘superbugs’.

Stock Code

HCG

Stock Exchange

ax

Helicon Group is involved in the business to identify and exploit niche market opportunities in the Biomedical markets in selected Asian markets with a China priority and to participate in the significant growth that has been projected for these markets over the next 25 years.

The Mission of the Helicon Group is to be a trusted vehicle and partner into the high end of the China and other selected Asian markets for innovative Western Biomedical products developed by small to medium sized research based pharmaceutical and medical device companies.

Stock Code

HTX

Stock Exchange

ax

Healthlinx (HTX) uses its proprietary “Cryptomics” technology to exploit evolutionary protein design to discover hidden or "cryptic" peptide fragments within existing larger proteins. The company develops drug candidates targeted at cancer, cardiovascular disease (CVD) and neuroinflammatory disorders. HTX is a Melbourne based, globally linked biotechnology company which was listed on the ASX in November 2003.

Stock Code

HGN

Stock Exchange

ax

HalcyGen Pharmaceuticals Limited (HGN) is a company that focuses on testing and improvement of generic drugs. It was listed on ASX on 29 June, 2007. The company is currently developing two potential "SuperGenerics" which are SUBA-Itraconazole and Minocycline which have been licensed from Mayne. SuperGenerics aim to improve generic reference pharmaceuticals to create safer, more efficacious and/or easier to use pharmacies.

Stock Code

GIA

Stock Exchange

ax

Giaconda (GIA) develop medical therapies that provides relief for patients suffering from serious gastointestinal (GI) diseases and disorders. Its product portfolio comprises of four therapeutic products and a pre-colonoscopy bowel preparation. These products mainly deal with approved and accepted compounds. The company was founded in 2004 as a vehicle to commercialise therapies for gastointestinal diseases and disorders. GIA was listed on the ASX in Sep 2005.

Stock Code

GEN

Stock Exchange

ax

Genesis Research and Development Corporation (GEN) is a biotechnology company with core technical expertise in the fields of genomics and immunology. GEN has developed an integrated research and discovery platform that includes proprietary sets of EST databases and microRNA libraries, extensive bioinformatics capability and cell-based screening technologies to identify novel targets for drug development

Stock Code

CTE

Stock Exchange

ax

Cryosite (CTE) provides specialised outsourced logistic services to a range of clients, including the research, medical, pharmaceutical, veterinary and biotechnology industries. The company's service includes the collection, processing and storage of cord blood stem cells for private use; and the archival storage of biological material for biological-based industries. In addition, CTE offers a computer-based management system for samples stored at customers own locations. Cryosite was listed on the ASX in May 2002. Its head office is situated in Sydney.

Stock Code

CGS

Stock Exchange

ax

Cogstate (CGS) specialises in the development and commercialisation of rapid, computerised tests for the measurement of cognition (brain function). CGS is basically a biotechnology company established in 1999 with its headquarters situated in Melbourne and it was listed on ASX on 13 February, 2004.